Trials / Conditions / Ovarian High Grade Serous Adenocarcinoma

Ovarian High Grade Serous Adenocarcinoma

15 registered clinical trials studyying Ovarian High Grade Serous Adenocarcinoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer NCT06580314	NRG Oncology	Phase 3
Recruiting	Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer NCT05998135	Emory University	Phase 2
Active Not Recruiting	Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage NCT05276973	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea NCT04616534	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	National Cancer Institute "Cancer Moonshot Biobank" NCT04314401	National Cancer Institute (NCI)	—
Active Not Recruiting	A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With NCT04092270	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurr NCT04034927	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube NCT03587311	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With R NCT02839707	National Cancer Institute (NCI)	Phase 2 / Phase 3
Active Not Recruiting	Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ova NCT02627443	National Cancer Institute (NCI)	Phase 1
Completed	Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, NCT02713386	NRG Oncology	Phase 1 / Phase 2
Active Not Recruiting	Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer NCT02345265	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary P NCT02659241	M.D. Anderson Cancer Center	EARLY_Phase 1
Completed	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707	Mayo Clinic	Phase 1
Active Not Recruiting	Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Canc NCT01116648	National Cancer Institute (NCI)	Phase 1 / Phase 2